Positive News SentimentPositive NewsNASDAQ:CUE Cue Biopharma (CUE) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free CUE Stock Alerts $1.62 -0.12 (-6.88%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$1.62▼$1.7550-Day Range$1.37▼$2.1852-Week Range$1.30▼$4.89Volume202,834 shsAverage Volume343,299 shsMarket Capitalization$79.04 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cue Biopharma alerts: Email Address Cue Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside392.3% Upside$8.00 Price TargetShort InterestBearish10.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.97) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.48 out of 5 starsMedical Sector271st out of 922 stocksPharmaceutical Preparations Industry116th out of 429 stocks 3.5 Analyst's Opinion Consensus RatingCue Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCue Biopharma has only been the subject of 4 research reports in the past 90 days.Read more about Cue Biopharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.20% of the outstanding shares of Cue Biopharma have been sold short.Short Interest Ratio / Days to CoverCue Biopharma has a short interest ratio ("days to cover") of 17.2, which indicates bearish sentiment.Change versus previous monthShort interest in Cue Biopharma has recently increased by 3.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCue Biopharma does not currently pay a dividend.Dividend GrowthCue Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCue Biopharma has received a 74.25% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Cue Biopharma is -0.58. Previous Next 3.8 News and Social Media Coverage News SentimentCue Biopharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cue Biopharma this week, compared to 1 article on an average week.Search Interest8 people have searched for CUE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added Cue Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cue Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.49% of the stock of Cue Biopharma is held by insiders.Percentage Held by InstitutionsOnly 35.04% of the stock of Cue Biopharma is held by institutions.Read more about Cue Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cue Biopharma are expected to grow in the coming year, from ($0.97) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cue Biopharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cue Biopharma is -1.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCue Biopharma has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cue Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIOnly buy gold this ONE day of the week What you’re looking at is the performance of gold each day of the week since the year 2000. As you can see, almost all of those gains hit on ONE day of the week… According to this gold expert, you DON’T want to just buy and hold gold on Fridays. And that’s because there’s a better way to leverage this Friday phenomenon. It’s called the “Weekend Gold Rush” and it’s a way to target $1,000 over the weekend from gold…Go here to discover the all-new Weekend Gold Rush. About Cue Biopharma Stock (NASDAQ:CUE)Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Read More CUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CUE Stock News HeadlinesMay 16, 2024 | markets.businessinsider.comCue Biopharma’s Promising Future: A Comprehensive Buy Rating JustificationMay 11, 2024 | finance.yahoo.comCue Biopharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)May 10, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | finance.yahoo.comCue Biopharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | globenewswire.comCue Biopharma to Present at the 20th Annual PEGS Boston SummitMay 7, 2024 | finance.yahoo.comCue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences ConferenceApril 24, 2024 | globenewswire.comCue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 9, 2024 | markets.businessinsider.comForecasting The Future: 4 Analyst Projections For Cue BiopharmaApril 9, 2024 | finanznachrichten.deCue Biopharma, Inc.: Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 9, 2024 | finance.yahoo.comCue Biopharma Inc (CUE) Q4 2023 Earnings Call Transcript Highlights: Strategic Alliances and ...April 8, 2024 | markets.businessinsider.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | globenewswire.comCue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsApril 8, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, April 08, 2024April 7, 2024 | markets.businessinsider.comCue Biopharma is about to announce earnings — here's what Wall Street expectsApril 2, 2024 | investorplace.comCUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 2, 2024 | finance.yahoo.comCue Biopharma to Host Business Update Call and WebcastApril 1, 2024 | msn.comCarisma to cut 37% of workforce, stock falls 8%March 13, 2024 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About Silence TherapeuticsFebruary 29, 2024 | finance.yahoo.comCue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 29, 2024 | globenewswire.comCue Biopharma's Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers SymposiumFebruary 27, 2024 | morningstar.comCue Biopharma Inc Ordinary SharesFebruary 26, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)See More Headlines Receive CUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cue Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CUE CUSIPN/A CIK1645460 Webwww.cuebiopharma.com Phone(617) 949-2680FaxN/AEmployees53Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+392.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-50,730,000.00 Net Margins-711.84% Pretax Margin-711.84% Return on Equity-128.30% Return on Assets-77.61% Debt Debt-to-Equity Ratio0.11 Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual Sales$5.49 million Price / Sales14.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book2.62Miscellaneous Outstanding Shares48,640,000Free Float45,000,000Market Cap$79.04 million OptionableOptionable Beta1.98 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Daniel R. Passeri J.D. (Age 63)M.Sc., CEO & Director Comp: $607.98kDr. Anish Suri Ph.D. (Age 50)President & Chief Scientific Officer Comp: $447.34kMs. Kerri-Ann Millar (Age 54)Chief Financial Officer Comp: $447.34kDr. Ronald D. Seidel III (Age 48)Ph.D., Co-Founder Comp: $316.63kMr. Colin G. Sandercock J.D. (Age 67)MSE, Senior VP, General Counsel & Secretary Comp: $381.42kDr. Matteo Levisetti M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsMilestone PharmaceuticalsNASDAQ:MISTAnnovis BioNYSE:ANVSEton PharmaceuticalsNASDAQ:ETONIO BiotechNASDAQ:IOBTBenitec BiopharmaNASDAQ:BNTCView All CompetitorsInsiders & InstitutionsCarlson Capital L PSold 100,000 shares on 5/14/2024Ownership: 0.041%Vanguard Group Inc.Bought 150,457 shares on 5/10/2024Ownership: 4.694%Monaco Asset Management SAMSold 7,500 shares on 5/9/2024Ownership: 0.688%Wedmont Private CapitalBought 20,000 shares on 4/10/2024Ownership: 0.082%Anish SuriBought 4,000 shares on 8/25/2023Total: $11,040.00 ($2.76/share)View All Insider TransactionsView All Institutional Transactions CUE Stock Analysis - Frequently Asked Questions Should I buy or sell Cue Biopharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CUE shares. View CUE analyst ratings or view top-rated stocks. What is Cue Biopharma's stock price target for 2024? 4 analysts have issued 12 month price targets for Cue Biopharma's stock. Their CUE share price targets range from $6.00 to $10.00. On average, they anticipate the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 392.3% from the stock's current price. View analysts price targets for CUE or view top-rated stocks among Wall Street analysts. How have CUE shares performed in 2024? Cue Biopharma's stock was trading at $2.64 at the beginning of 2024. Since then, CUE shares have decreased by 38.4% and is now trading at $1.6250. View the best growth stocks for 2024 here. When is Cue Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CUE earnings forecast. How were Cue Biopharma's earnings last quarter? Cue Biopharma, Inc. (NASDAQ:CUE) issued its quarterly earnings data on Thursday, May, 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.05. The firm earned $1.72 million during the quarter, compared to analyst estimates of $0.73 million. Cue Biopharma had a negative net margin of 711.84% and a negative trailing twelve-month return on equity of 128.30%. What other stocks do shareholders of Cue Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cue Biopharma investors own include Provention Bio (PRVB), NVIDIA (NVDA), OPKO Health (OPK), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), AT&T (T) and Advanced Micro Devices (AMD). Who are Cue Biopharma's major shareholders? Cue Biopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.69%), Monaco Asset Management SAM (0.69%), Wedmont Private Capital (0.08%), Carlson Capital L P (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Aaron GL Fletcher, Anish Suri, Daniel R Passeri, Kerri-Ann Millar and Peter A Kiener. View institutional ownership trends. How do I buy shares of Cue Biopharma? Shares of CUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CUE) was last updated on 5/26/2024 by MarketBeat.com Staff From Our Partners[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 MediaClaim Your Complimentary Bitcoin RewardCrypto Swap Profits$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyElon’s New Device is About to Shock the WorldInvestorPlaceNew Options need New Trading StrategiesNetpicksWrite this ticker symbol down…StocksToTradeElon to Transform U.S. Economy? Porter & CompanyBill Clinton Backing Biden Replacement???The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cue Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
